SMMT - サミット・セラピュ―ティクス （Summit Therapeutics plc）

During the last session, Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday gain of 4.63% or $0.05. The 52-week high for the SMMT share is $8.39, that puts it down … Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? Read More »

Summit Therapeutics (SMMT) stock dropped ~17% postmarket after the firm announced a rights offering for shareholders of record as of market close on Jul

Summit Therapeutics (SMMT) appoints Ankur Dhingra as CFO, effective immediately.Mr

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.

Summit Therapeutics press release (SMMT): Q1 GAAP EPS of -$0.22.Revenue of $0.25M (+31.6% Y/Y).

During the last session, Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares were 1.08 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday gain of 4.63% or $0.05. The 52-week high for the SMMT share is $8.39, that puts it down … Boom Or Bust: Where Does Summit Therapeutics Inc. (NASDAQ: SMMT) Stock Go From Here? Read More »

Summit Therapeutics (SMMT) stock dropped ~17% postmarket after the firm announced a rights offering for shareholders of record as of market close on Jul

Summit Therapeutics (SMMT) appoints Ankur Dhingra as CFO, effective immediately.Mr

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD ) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. JanOne Inc. (NASDAQ: JAN ) gained 66.5% to close at $3.73 after the company announced it sold GeoTraq to SPYR Technologies in a $13.5 million transaction. Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 44.9% to settle at $1.40 after the company announced results of its solid-state polymer battery testing with the Battery Innovation Center in Indiana. Studio City International Holdings Limited (NASDAQ: MSC ) gained 43.3% to close at $3.21. CatchMark Timber Trust, Inc. (NYSE: CTT ) shares climbed 42.1% to close at $11.79 after the company and PotlatchDeltic announced they have entered into a definitive agreement to combine in an all-stock transaction. Xcel Brands, Inc. (NASDAQ: XELB ) gained 36.7% to settle at $1.49 after the company announced WHP will purchase a controlling 70% interest in fashion brand Isaac Mizrahi.

Summit Therapeutics press release (SMMT): Q1 GAAP EPS of -$0.22.Revenue of $0.25M (+31.6% Y/Y).

Analysts expect that Summit Therapeutics Inc. (NASDAQ:SMMT) will post ($0.29) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Summit Therapeutics earnings. Summit Therapeutics posted earnings of ($0.25) per share during the same quarter last year, which would indicate a negative year over year growth []

Citigroup Inc. cut its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT) by 53.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,165 shares of the companys stock after selling 8,167 shares during the period. Citigroup Inc.s holdings in Summit Therapeutics were []

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. Mr. Clark is currently a partner at Wilson Sonsini Goodrich & Rosati (WSGR) based out of the firms Palo Alto, CA, office.

Futures Bounce On Evergrande Reprieve With Fed Looming Despite today''s looming hawkish FOMC meeting in which Powell is widely expected to unveil that tapering is set to begin as soon as November and where the Fed''s dot plot may signal one rate hike in 2022, futures climbed as investor concerns over China''s Evergrande eased after the property developer negotiated a domestic bond payment deal. Commodities rallied while the dollar was steady. Contracts on the S&P 500 and Nasdaq 100 flipped from losses to gains as Chinas central bank boosted liquidity when it injected a gross 120BN in yuan, the most since January ... and investors mulled a vaguely-worded statement from the troubled developer about an interest payment. S&P 500 E-minis were up 23.0 points, or 0.53%, at 7:30 a.m. ET. Dow E-minis were up 199 points, or 0.60%, and Nasdaq 100 E-minis were up 44.00 points, or 0.29%. Among individual stocks, Fedex fell 5.8% after the delivery company cut its profit outlook on higher costs and stalled growth in shipments.